330 related articles for article (PubMed ID: 19833956)
1. Alzheimer's biomarker initiative hits its stride.
Miller G
Science; 2009 Oct; 326(5951):386-9. PubMed ID: 19833956
[No Abstract] [Full Text] [Related]
2. [MCI-plus: mild cognitive impairment with rapid progression. Part II: Biomarkers and research methods].
Förstl H; Werheid K; Ulm K; Schönknecht P; Schmidt R; Pantel J; Hörr R; Gutzmann H; Gertz HJ; Frölich L; Bickel H
Dtsch Med Wochenschr; 2009 Jan; 134(3):88-91. PubMed ID: 19142839
[TBL] [Abstract][Full Text] [Related]
3. No association of CSF biomarkers with APOEepsilon4, plaque and tangle burden in definite Alzheimer's disease.
Engelborghs S; Sleegers K; Cras P; Brouwers N; Serneels S; De Leenheir E; Martin JJ; Vanmechelen E; Van Broeckhoven C; De Deyn PP
Brain; 2007 Sep; 130(Pt 9):2320-6. PubMed ID: 17586559
[TBL] [Abstract][Full Text] [Related]
4. Imaging and in vivo quantitation of beta-amyloid: an exemplary biomarker for Alzheimer's disease?
Nichols L; Pike VW; Cai L; Innis RB
Biol Psychiatry; 2006 May; 59(10):940-7. PubMed ID: 16487944
[TBL] [Abstract][Full Text] [Related]
5. New tests for Alzheimer's disease.
Health News; 2006 Jun; 12(6):2. PubMed ID: 16826618
[No Abstract] [Full Text] [Related]
6. Cerebrospinal fluid biomarkers in Alzheimer's disease: are the hypotheses more dynamic than the biomarkers?
Spies PE; Verbeek MM; Olde Rikkert MG; Claassen JA
J Am Geriatr Soc; 2010 Aug; 58(8):1619-20. PubMed ID: 20942893
[No Abstract] [Full Text] [Related]
7. [Interest of CSF beta-amyloid1-42 and t-tau protein level determinations for the diagnosis of Alzheimer's disease].
Smach MA; Charfeddine B; Lammouchi T; Dridi H; Ben Othman L; Bennamou S; Limem K
Ann Biol Clin (Paris); 2008; 66(5):531-5. PubMed ID: 18957342
[TBL] [Abstract][Full Text] [Related]
8. To tap or not to tap: cerebrospinal fluid biomarkers of Alzheimer's disease.
Growdon JH
Ann Neurol; 1998 Jul; 44(1):6-7. PubMed ID: 9667586
[No Abstract] [Full Text] [Related]
9. [Biological markers for diagnosis of Alzheimer's disease].
Takeda M; Tanaka T; Kudo T; Okochi M; Kamino A; Tagami S
Seishin Shinkeigaku Zasshi; 2004; 106(12):1610-4. PubMed ID: 15770965
[No Abstract] [Full Text] [Related]
10. Neuropsychiatric correlates of cerebrospinal fluid biomarkers in Alzheimer's disease.
Skogseth R; Mulugeta E; Jones E; Ballard C; Rongve A; Nore S; Alves G; Aarsland D
Dement Geriatr Cogn Disord; 2008; 25(6):559-63. PubMed ID: 18536520
[TBL] [Abstract][Full Text] [Related]
11. Validation of Alzheimer's disease CSF and plasma biological markers: the multicentre reliability study of the pilot European Alzheimer's Disease Neuroimaging Initiative (E-ADNI).
Buerger K; Frisoni G; Uspenskaya O; Ewers M; Zetterberg H; Geroldi C; Binetti G; Johannsen P; Rossini PM; Wahlund LO; Vellas B; Blennow K; Hampel H
Exp Gerontol; 2009 Sep; 44(9):579-85. PubMed ID: 19539742
[TBL] [Abstract][Full Text] [Related]
12. Monitoring the amyloid beta-peptide in vivo--caveat emptor.
Thompson PW; Lockhart A
Drug Discov Today; 2009 Mar; 14(5-6):241-51. PubMed ID: 19135168
[TBL] [Abstract][Full Text] [Related]
13. The diagnosis of Alzheimer disease before it is Alzheimer dementia.
Frisoni GB; Padovani A; Wahlund LO
Arch Neurol; 2003 Jul; 60(7):1023; author reply 1023-4. PubMed ID: 12873864
[No Abstract] [Full Text] [Related]
14. CSF biomarkers in relationship to cognitive profiles in Alzheimer disease.
van der Vlies AE; Verwey NA; Bouwman FH; Blankenstein MA; Klein M; Scheltens P; van der Flier WM
Neurology; 2009 Mar; 72(12):1056-61. PubMed ID: 19307538
[TBL] [Abstract][Full Text] [Related]
15. New tests for AD.
Health News; 2006 Apr; 12(4):15. PubMed ID: 16578901
[No Abstract] [Full Text] [Related]
16. Concentrations of metals, beta-amyloid and tau-markers in cerebrospinal fluid in patients with Alzheimer's disease.
Gerhardsson L; Blennow K; Lundh T; Londos E; Minthon L
Dement Geriatr Cogn Disord; 2009; 28(1):88-94. PubMed ID: 19672066
[TBL] [Abstract][Full Text] [Related]
17. CSF biomarkers predict rate of cognitive decline in Alzheimer disease.
Kester MI; van der Vlies AE; Blankenstein MA; Pijnenburg YA; van Elk EJ; Scheltens P; van der Flier WM
Neurology; 2009 Oct; 73(17):1353-8. PubMed ID: 19858456
[TBL] [Abstract][Full Text] [Related]
18. Usability of cerebrospinal fluid biomarkers in a tertiary memory clinic.
Brandt C; Bahl JC; Heegaard NH; Waldemar G; Johannsen P
Dement Geriatr Cogn Disord; 2008; 25(6):553-8. PubMed ID: 18536519
[TBL] [Abstract][Full Text] [Related]
19. Improved discrimination of autopsy-confirmed Alzheimer's disease (AD) from non-AD dementias using CSF P-tau(181P).
Koopman K; Le Bastard N; Martin JJ; Nagels G; De Deyn PP; Engelborghs S
Neurochem Int; 2009 Sep; 55(4):214-8. PubMed ID: 19524111
[TBL] [Abstract][Full Text] [Related]
20. Biological markers in cerebrospinal fluid (CSF) and evaluation of in vitro effect of CSF on PC12 cell line viability in Alzheimer's disease.
Yaka E; Egrilmez MY; Keskinoglu P; Cavdar Z; Genc S; Genc K; Iyilikci L; Yener GG
Cell Biochem Funct; 2009 Aug; 27(6):395-401. PubMed ID: 19639578
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
